论文部分内容阅读
目的:探讨骨化三醇对慢性充血性心力衰竭(CHF)患者血清脑钠肽、基质金属蛋白酶-9(MMP-9)及左心室质量指数(LVMI)的影响。方法:选择80例CHF患者,随机分为骨化三醇治疗组及常规治疗组各40例,同期收集80名门诊健康体检者为对照组。研究期1年,所有研究对象均在研究初始及研究结束时接受血清钙、脑钠肽、MMP-9水平及心脏超声检测,计算研究对象的LVMI,并记录两研究组患者心血管事件发生率及不良反应的发生率。结果:研究结束时,骨化三醇治疗组患者的脑钠肽、MMP-9水平明显低于常规治疗组(P<0.05),其LVMI虽低于常规治疗组,但比较差异无统计学意义(P>0.05)。两组间的心血管事件及不良反应发生率比较差异无统计学意义(P>0.05)。结论:骨化三醇可能具有降低CHF患者血清脑钠肽、MMP-9水平的作用。
Objective: To investigate the effects of calcitriol on serum brain natriuretic peptide, matrix metalloproteinase-9 (MMP-9) and left ventricular mass index (LVMI) in patients with chronic congestive heart failure (CHF) Methods: Eighty CHF patients were selected and randomly divided into calcitriol treatment group and conventional treatment group, 40 cases each. During the same period, 80 outpatients were selected as control group. During the study period of 1 year, all subjects received serum calcium, brain natriuretic peptide, MMP-9 levels and echocardiography at the initiation of the study and at the end of the study. LVMI was calculated and the incidence of cardiovascular events was recorded in both study groups And the incidence of adverse reactions. Results: At the end of the study, the levels of brain natriuretic peptide and MMP-9 in the calcitriol treatment group were significantly lower than those in the conventional treatment group (P <0.05). Although the LVMI was lower than the conventional treatment group, the difference was not statistically significant (P> 0.05). There was no significant difference in the incidence of cardiovascular events and adverse reactions between the two groups (P> 0.05). Conclusion: Calcitriol may reduce the serum levels of brain natriuretic peptide and MMP-9 in CHF patients.